Ivonescimab in advanced NSCLC: is progression-free survival enough, or are overall survival data also needed?
- PMID: 40057331
- DOI: 10.1016/S0140-6736(25)00369-1
Ivonescimab in advanced NSCLC: is progression-free survival enough, or are overall survival data also needed?
Conflict of interest statement
KS reports research funding to her institution from Black Diamond Therapeutics, Harpoon Therapeutics, Genentech, Merck, AstraZeneca, and Lilly. KLR reports honoraria for working as a consultant for Amgen, AstraZeneca, Blueprint, Daiichi Sankyo, Genentech, GlaxoSmithKline, Janssen, Lilly, Mirati, Novartis, Novocure, and Pfizer; and research funding to her institution from Genentech, Blueprint, Daiichi Sankyo, Elevation Oncology, and Janssen.
Comment on
-
Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China.Lancet. 2025 Mar 8;405(10481):839-849. doi: 10.1016/S0140-6736(24)02722-3. Lancet. 2025. PMID: 40057343 Clinical Trial.
Publication types
LinkOut - more resources
Full Text Sources